Alaunos Therapeutics, Inc.
TCRT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $5 | $2,922 | $398 |
| % Growth | 100% | -99.8% | 634.2% | – |
| Cost of Goods Sold | $0 | $4,803 | $0 | $0 |
| Gross Profit | $10 | -$4,798 | $2,922 | $398 |
| % Margin | 100% | -95,960% | 100% | 100% |
| R&D Expenses | $362 | $16,279 | $25,018 | $49,643 |
| G&A Expenses | $4,460 | $12,219 | $13,142 | $27,564 |
| SG&A Expenses | $4,460 | $12,219 | $13,142 | $27,564 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $971 | -$133 | $740 |
| Operating Expenses | $4,822 | $29,469 | $38,027 | $77,947 |
| Operating Income | -$4,812 | -$34,267 | -$35,105 | -$77,549 |
| % Margin | -48,120% | -685,340% | -1,201.4% | -19,484.7% |
| Other Income/Exp. Net | $133 | -$873 | -$2,625 | -$1,202 |
| Pre-Tax Income | -$4,679 | -$35,140 | -$37,730 | -$78,751 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,679 | -$35,140 | -$37,730 | -$78,751 |
| % Margin | -46,790% | -702,800% | -1,291.2% | -19,786.7% |
| EPS | -2.92 | -21.97 | -25.97 | -53.8 |
| % Growth | 86.7% | 15.4% | 51.7% | – |
| EPS Diluted | -2.92 | -21.97 | -25.97 | -53.8 |
| Weighted Avg Shares Out | 1,601 | 1,600 | 1,448 | 1,429 |
| Weighted Avg Shares Out Dil | 1,601 | 1,600 | 1,448 | 1,429 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1,921 | $3,154 | $1,189 |
| Depreciation & Amortization | $2 | $2,315 | $2,759 | $2,597 |
| EBITDA | -$4,677 | -$30,904 | -$31,817 | -$74,965 |
| % Margin | -46,770% | -618,080% | -1,088.9% | -18,835.4% |